Results 71 to 80 of about 153,995 (247)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Molecular characterization and antiviral analyses of porcine type III interferons

, 2010
Type III interferons (IFNs) are a family of recently identified antiviral cytokines. One to 3 paralogs have been identified in several species; however, little information is available about type III IFNs in pigs.
Rowland, Raymond R. R., Frank Blecha, Sang, Yongming, Blecha, Frank, Yongming Sang, Raymond R.R. Rowland   +5 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up by interferons?

, 2013
Interleukin (IL)-10 and IL-22 are key members of the IL-10 cytokine family that share characteristic properties such as defined structural features, usage of IL-10R2 as one receptor chain, and activation of signal transducer and activator of ...
Heiko Mühl, Heiko eMühl, Mühl, Heiko
core   +1 more source

IFN-gamma impairs release of IL-8 by IL-1beta-stimulated A549 lung carcinoma cells [PDF]

, 2008
Background Production of interferon (IFN)-gamma is key to efficient anti-tumor immunity. The present study was set out to investigate effects of IFNgamma on the release of the potent pro-angiogenic mediator IL-8 by human A549 lung carcinoma cells ...
Bernhard Zwissler, Zwißler, Bernhard, Sadik, Christian David, Pfeilschifter, Josef (Prof. Dr.), Heiko Mühl, Malte Bachmann, Muehl, Heiko, Sadik, Christian D., Josef Pfeilschifter, Christian D Sadik, Pfeilschifter, Josef, Bachmann, Malte, Boost, Kim Alexander, Mühl, Heiko, Kim A Boost, Boost, Kim A.   +15 more
core   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

Type III interferon enhances the direct antitumor activity of type I interferon

, 2011
The antitumor activities of type III interferon (IFN) (interleukin (IL)-28 and IL-29) and the combination between type III IFN and type I IFN (IFN-α) were evaluated in in vitro and in vivo studies using human non-small cell lung cancer (NSCLC).
藤江, 瞳, 牛, 凱軍, 渡辺, みか, 鈴木, 貴, 沼崎, 宗夫, 田中, 利明, 中山, 勝敏, 田川, 雅敏   +7 more
core   +1 more source

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. [PDF]

PLoS Pathogens, 2010
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly.
Matthew B Frieman, Jun Chen, Thomas E Morrison, Alan Whitmore, William Funkhouser, Jerrold M Ward, Elaine W Lamirande, Anjeanette Roberts, Mark Heise, Kanta Subbarao, Ralph S Baric   +10 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Species-Specific Contribution of the Four C-Terminal Amino Acids of Influenza A Virus NS1 Protein to Virulence [PDF]

, 2010
Large-scale sequence analyses of influenza viruses revealed that nonstructural 1 (NS1) proteins from avian influenza viruses have a conserved C-terminal ESEV amino acid motif, while NS1 proteins from typical human influenza viruses have a C-terminal RSKV
Loupias, Josiane, Lacroux, Caroline, Peralta, Brigitte, Soubies, S. M., Soubiès, Sébastien, Loupias, Josyane, Costes, Pierrette, Guérin, Jean-Luc, Volmer, C., Volmer, Christelle, Croville, Guillaume, Soubies, Sebastien Mathieu, Volmer, Romain   +12 more
core   +1 more source